Thyroid Hormones membrane receptor, Integrin αvβ3 as a potential prognostic marker of chemotherapy response in breast cancer

DIAZ ALBUJA, JOHANNA; PAULAZO, ALEJANDRA; ROSEMBLIT, CINTHIA; CAYROL, FLORENCIA; DEBERNARDI, MERCEDES; DÍAZ FLAQUÉ, MARÍA CELESTE; STERLE, HELENA; CAMPOS HAEDO, M.N.; CREMASCHI, GRACIELA A.

Congreso; Endocrine sOCIETY aNNUAL mEETING; 2022

Despite the development of novel therapies, breast cancer (BC) tumors are treatedwith conventional therapy sooner or later. Due to tumor heterogeneity, it is necessaryto define new biomarkers to identify groups with different molecular characteristic toimprove the correct treatment decision. The impact of thyroid status in BC growth haspreviously been studied. In particular, it has been found alterations of thyroid functionduring chemotherapy BC treatment and demonstrated that T3 induceschemosensitization of BC cells. However, the relationship between thyroid hormones(THs) membrane receptor, integrin αvβ3 and BC response to chemotherapy remainsunclear. The aim of this study is to evaluate the relationship between THs and integrinαvβ3 expression as prognostic value in BC patients.The mRNA expression of ITGB3 in TCGA-PanCancer Atlas, BC dataset (1084patients) were associated with worse overall survival. Moreover, ITGB3 mRNAexpression was significantly correlated with genes encoding multidrugresistance protein transporters MDR1 and BCRP such as ABCB1 and ABCG2,(Pearson, R score >0.3 and p